PHI with Sinonasal polyps
How does this condition affect your private health insurance?
Nasennebenhöhlenpolypen, or nasal polyps, are soft, non-cancerous growths originating from the inflamed lining of the nasal passages or paranasal sinuses. They commonly develop in individuals with chronic rhinosinusitis, asthma, allergies, or aspirin sensitivity. Symptoms include persistent nasal obstruction, decreased sense of smell, facial pressure, and postnasal drip. While not malignant, large polyps can significantly impair breathing, sleep quality, and lead to recurrent sinus infections. Treatment typically involves corticosteroids and, in persistent cases, surgical removal. However, polyps frequently recur, necessitating long-term management to control symptoms and prevent re-growth.
PKV Risk Assessment
However, some specialized PHI providers may insure you with a surcharge of up to 20%.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Weeks to months without treatment; symptoms improve within days to weeks with initial medical therapy.
Duration of Illness (Lifetime)
Often a chronic, recurrent condition requiring ongoing management; recurrence is common even after surgery.
Cost of Treatment (Initial)
Several hundred to a few thousand dollars (initial consultation, diagnostics like CT scan, medications).
Cost of Treatment (Lifetime)
Several thousand to tens of thousands of dollars or more (recurrent visits, medications, potential multiple surgeries, biologics in severe cases).
Mortality Rate
Extremely low (nearly 0%). Nasal polyps themselves are not life-threatening.
Risk of Secondary Damages
Moderate to high (e.g., chronic sinusitis, anosmia, sleep disturbances, reduced quality of life, impact on breathing).
Probability of Full Recovery
Low (recurrence is common, often requiring long-term management to control symptoms rather than achieving permanent cure without consequences).
Underlying Disease Risk
Moderate to high (common associations include asthma, aspirin-exacerbated respiratory disease, allergic fungal rhinosinusitis, and cystic fibrosis).